Lexaria Nicotine LLC, (16.667% owned by Altria Ventures Inc.) holds the exclusive rights to the use or sublicense of DehydraTECH with nicotine molecules.
In the six months ended February 28, 2025, the Company recognized revenue of $ 357,923 on a consolidated basis. Two customers accounted for 100 % of that total.
In January 2021, Lexaria’s wholly-owned subsidiary, Lexaria CanPharm ULC sold its exclusive license rights and assigned all sublicenses for the use of DehydraTECH with non-pharmaceutical THC-related …
Reciprocal relationship from MO graph: Reciprocal relationship from LEXX graph: Reciprocal relationship from MO graph: Reciprocal relationship from LEXX graph: Reciprocal relationship from MO graph: …
ments do not include any adjustments that might be necessary if the Company is not able to continue as a going concern. F-6 Table of Contents % of Lexaria Nicotine LLC and the remaining % is owned by…
l studies on DehydraTECH-enhanced GLP-1 and GIP drug formulations to determine if better efficacy with reduced side effects will occur utilizing the DehydraTECH patented technology. 11 Table of Conte…
ive licenses: · Non-exclusive license with Hill Inc. for all product formats globally; · Non-exclusive license with Boldt Runners Corporation for oral pouch and oral mulch products in the US, South A…
ive licenses: · Non-exclusive license with Hill Inc. for all product formats globally; · Non-exclusive license with Boldt Runners Corporation for oral pouch and oral mulch products in the US, South A…
l studies on DehydraTECH-enhanced GLP-1 and GIP drug formulations to determine if better efficacy with reduced side effects will occur utilizing the DehydraTECH patented technology. 11 Table of Conte…
l studies on DehydraTECH-enhanced GLP-1 and GIP drug formulations to determine if better efficacy with reduced side effects will occur utilizing the DehydraTECH patented technology. 11 Table of Conte…
ive licenses: · Non-exclusive license with Hill Inc. for all product formats globally; · Non-exclusive license with Boldt Runners Corporation for oral pouch and oral mulch products in the US, South A…
Lexaria Bioscience Corp. Debt Obligations
Instrument
Description
Confidence
Evidence
LEXX-DEBT
Debt stack $94,386
90%
Market cache reports total debt of $94,386.
LEXX-DEBT-10659
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-08-31.
LEXX-DEBT-10658
Warrants outstanding: 2052140
90%
xbrl warrant detail from xbrl 2026-02-28.
Lexaria Bioscience Corp. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Lexaria Bioscience Corp..
Lexaria Bioscience Corp. Ownership
Holder
Name
Confidence
Evidence
LEXX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 28 tracked holders.
